Voxelotor is a Small Molecule owned by Pfizer, and is involved in 36 clinical trials, of which 22 were completed, 12 are ongoing, and 2 are planned. Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.

The revenue for Voxelotor is expected to reach a total of $14.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Voxelotor NPV Report.

Voxelotor was originated by University of California and is currently owned by Pfizer. Global Blood Therapeutics is the other company associated in development or marketing of Voxelotor.

Voxelotor Overview

Voxelotor (Oxbryta) is a hematologic agent. It is formulated as film coated tablets for oral route of administration. Voxelotor is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. Oxbryta is indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older, either as monotherapy or in combination with hydroxycarbamide.

Voxelotor (GBT-440) is under development for the treatment of sickle cell disease. The therapeutic candidate is administered through oral route. It acts by targeting hemoglobin. The drug candidate is developed based on Shape platform. The drug candidate was under development for the treatment of acute hypoxemic pulmonary fibrosis.

Global Blood Therapeutics Overview

Global Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company. The company offers Voxelotor which is used for the treatment of sickle cell disease, or SCD, in adults and children. GBT’s pipeline also includes GBT021601 which is a next-generation hemoglobin polymerization inhibitor that is in Phase 1 development. The company also develops therapies that are in preclinical and preliminary clinical stages for the treatment of acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms for blood-based disorders. GBT is headquartered in South San Francisco, California, the US. Global Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company. The company offers Voxelotor which is used for the treatment of sickle cell disease, or SCD, in adults and children. GBT’s pipeline also includes GBT021601 which is a next-generation hemoglobin polymerization inhibitor that is in Phase 1 development. The company also develops therapies that are in preclinical and preliminary clinical stages for the treatment of acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms for blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

Quick View – Voxelotor

Report Segments
  • Innovator (NME)
Drug Name
  • Voxelotor
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.